Parsatuzumab
Parsatuzumab
Parsatuzumab (pronunciation: par-sa-too-zoo-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that is still under investigation in clinical trials.
Etymology
The name "Parsatuzumab" is derived from the International Nonproprietary Names (INN), where "zu" denotes humanized antibody, "mab" stands for monoclonal antibody, and "parsa" is a unique stem that doesn't have a specific meaning.
Mechanism of Action
Parsatuzumab works by binding to specific proteins found on the surface of cancer cells. This binding can block the growth of the cancer cells and can also stimulate the immune system to attack the cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight cancer, infections, and other diseases.
- Clinical trial: A research study that tests how well new medical approaches work in people.
See Also
External links
- Medical encyclopedia article on Parsatuzumab
- Wikipedia's article - Parsatuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski